LS Mtron Participates in ‘Agritechnica 2019’ Accelerating Its Advance into Europe
28.11.2019 11:00:00 EET | Business Wire | Press release
LS Mtron (CEO Andy Kim) announced on November 28 that it had participated in ‘Agritechnica 2019’ held in Hanover, Germany from November 10 through the 16.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005173/en/
LS Mtron of Korea, specializing in industrial machines and state-of-the-art components, participated in ‘Agritechnica 2019’. The company has participated in the exhibition since 2015. This year, LS Mtron had a booth covering 205 square meters to showcase its products. Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors. (Photo: Business Wire)
Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors.
In 2003, LS Mtron was spun off from LG Group as an affiliate specializing in industrial machines and state-of-the-art components. Last year, sales amounted to KRW1.1 trillion. LS Mtron, with its annual production capacity of 50,000 units, has the largest share of the Korean tractor market. The company also exports to more than 40 countries, including the US, Brazil, China, etc., with its global production and sales bases playing key roles.
Significantly, last year, LS Mtron received the ‘Tractor of the Year’ award at the North American Equipment Dealers Association’s ‘Dealer’s Choice’ awards for the 5th consecutive years. In addition, LS Mtron is ‘Korea’s No.1 Tractor’ maker that is using ICT technology to lead the agricultural machinery industry in remote diagnostic services and cutting-edge autonomous tractor technologies.
This year, LS Mtron had a booth covering 205m2 to showcase its products in ‘Agritechnica 2019’. The slogan for the event ‘Change Your Standard’ was chosen to present maximum reliability and rationality to European customers and change the anchor purchases with excellent product fundamentals, innovative design, compelling performance, full support for dealers, and supplying parts at the right place at the right time.
LS Mtron introduced 7 models ranging from an 18ps Sub-compact model to the 150ps Row-crop model which can appeal to European customers. The futuristic ‘MTX (tentative)’ concept tractor is thought to have taken the streamlined design of existing products a step further. The company has applied a strong and sharp design language with headlamps resembling the fierce eyes of an angry bull that clearly say that LS Mtron products can provide ‘powerful and faithful work performance’. The Utility tractor, 100ps ‘XP’ model, scheduled to be launched in Europe in 2020 especially drew the attention of visitors. The XP tractor, based on its powerful engine and cutting-edge technology, makes it possible to move forward and backward easily without the manual operation of clutches when using the improved power shuttle. And as it comes standard with LED headlamps instead of halogen, its workability at night has also been improved.
In particular, during the exhibition, LS Mtron entered into an MOU for the development of e-Tractors with Austria’s AVL, the world’s best powertrain development and testing company. The two companies are planning to capitalize on this MOU to develop Sub-Compact e-Tractors and produce highly-efficient and eco-friendly tractors. LS Mtron will proactively present the direction of its eco-friendly models of the future to the European market and introduce a broader lineup of various models to make inroads into the lawn & garden and landscaping markets.
LS Mtron is planning to leverage its participation in the exhibition to develop new models and technologies customized for Europe. The company has established a roadmap for the launch of new models starting with the new premium MT2 and utility tractors in 2020 and plans to proactively respond to environmental protection and regulatory changes by successively launching new models based on the Stage V engine in 2021. In January 2020, LS Mtron will become the first Korean company in the industry to restrict the use of hazardous materials containing phthalates, thereby promoting the safety of customers and eco-friendliness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191128005173/en/
Contact information
LS Mtron
Jae Woo Lee
+82-31-8045-9667
unforgiven81@lsmtron.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
